| (210) | Number of the EPO application | 18794202 |
| (220) | Filing date of the EPO application | 2018.05.03 |
| (80) | EPO patent specification publication (B) | EPB nr. 19/2023, 2023.05.10 |
| (110) | EPO patent number | 3628049 |
| (11) | Number of the document | MD 3628049 T2 |
| (21) | Number of the application | e 2020 0304 |
| (71) | Name(s) of applicant(s), code of the country | ACCELERON PHARMA INC., US; |
| (72) | Name(s) of inventor(s), code of the country | KUMAR Ravindra, US;
SAKO Dianne S., US; |
| (73) | Name(s) of owner(s), code of the country | ACCELERON PHARMA INC., US; |
| (54) | Title of the invention | TGF-beta receptor type ii fusion proteins and uses thereof |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07K 14/71 (2006.01.01); C07K 16/46 (2006.01.01); A61K 38/17 (2006.01.01); A61P 9/12 (2006.01.01); A61P 9/10 (2006.01.01); A61P 13/12 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.04.30 |
| (49) | Date of publication of the translation of the validated European patent specification | 2023.10.31 |
| (30) | Priority | 201762501229 P, 2017.05.04, US; 201762510422 P, 2017.05.24, US; 201762578674 P, 2017.10.30, US |
| (74) | Patent attorney | (Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2018/030816, 2018.05.03 |
| (87) | International publication | WO 2018/204594, 2018.11.08 |